Renaissance Technologies LLC Grows Stock Holdings in MiNK Therapeutics, Inc. (NASDAQ:INKT)

Renaissance Technologies LLC lifted its position in MiNK Therapeutics, Inc. (NASDAQ:INKT) by 21.5% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 127,841 shares of the company’s stock after buying an additional 22,613 shares during the quarter. Renaissance Technologies LLC’s holdings in MiNK Therapeutics were worth $121,000 at the end of the most recent quarter.

MiNK Therapeutics Stock Up 0.1 %

Shares of INKT opened at $0.67 on Monday. The company has a market cap of $23.30 million, a P/E ratio of -1.12 and a beta of 0.06. MiNK Therapeutics, Inc. has a fifty-two week low of $0.57 and a fifty-two week high of $1.90. The firm’s 50 day moving average price is $0.78 and its 200 day moving average price is $0.90.

MiNK Therapeutics (NASDAQ:INKT) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.03. Research analysts forecast that MiNK Therapeutics, Inc. will post -0.33 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $9.00 target price on shares of MiNK Therapeutics in a research report on Wednesday, October 9th.

MiNK Therapeutics Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.